Q1 EPS Estimate for Jazz Pharmaceuticals Boosted by Analyst

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Stock analysts at Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for Jazz Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 18th. Zacks Research analyst S. Ganoria now expects that the specialty pharmaceutical company will post earnings per share of $3.51 for the quarter, up from their previous forecast of $3.17. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q2 2025 earnings at $4.70 EPS, Q3 2025 earnings at $5.30 EPS, Q4 2025 earnings at $5.51 EPS, FY2025 earnings at $19.02 EPS, Q1 2026 earnings at $3.13 EPS, Q2 2026 earnings at $4.79 EPS, Q3 2026 earnings at $5.84 EPS, Q4 2026 earnings at $5.90 EPS, FY2026 earnings at $19.66 EPS and FY2027 earnings at $20.50 EPS.

Several other research firms have also commented on JAZZ. Needham & Company LLC reaffirmed a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, March 5th. JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Truist Financial raised their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. HC Wainwright raised their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Finally, Cantor Fitzgerald lowered Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Buy” and an average price target of $187.71.

Jazz Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ:JAZZ opened at $138.76 on Friday. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $148.06. The stock has a market cap of $8.43 billion, a price-to-earnings ratio of 19.54, a PEG ratio of 1.04 and a beta of 0.44. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The business has a 50-day moving average price of $131.41 and a 200-day moving average price of $121.61.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,140 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $137.81, for a total value of $157,103.40. Following the sale, the chief accounting officer now directly owns 7,012 shares of the company’s stock, valued at $966,323.72. The trade was a 13.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the sale, the chief executive officer now directly owns 439,744 shares in the company, valued at $53,785,088.64. This represents a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,736 shares of company stock valued at $4,022,825. Company insiders own 4.20% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after acquiring an additional 100,112 shares during the last quarter. Centre Asset Management LLC purchased a new position in Jazz Pharmaceuticals during the fourth quarter worth approximately $9,335,000. Moloney Securities Asset Management LLC purchased a new position in Jazz Pharmaceuticals during the fourth quarter worth approximately $464,000. Pacer Advisors Inc. lifted its position in Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after buying an additional 278,465 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after buying an additional 48,708 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.